Tourmaline Bio, Inc. (TRML)

Tourmaline Bio Statistics

Total Valuation

Tourmaline Bio has a market cap or net worth of $1.23 billion. The enterprise value is $989.47 million.

Market Cap	1.23B
Enterprise Value	989.47M

Important Dates

The next estimated earnings date is Thursday, November 6, 2025, before market open.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Tourmaline Bio has 25.76 million shares outstanding. The number of shares has increased by 53.98% in one year.

Current Share Class	25.76M
Shares Outstanding	25.76M
Shares Change (YoY)	+53.98%
Shares Change (QoQ)	+0.25%
Owned by Insiders (%)	8.52%
Owned by Institutions (%)	59.81%
Float	13.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	4.73
P/TBV Ratio	4.74
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 24.68, with a Debt / Equity ratio of 0.00.

Current Ratio	24.68
Quick Ratio	23.70
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -29.62% and return on invested capital (ROIC) is -21.42%.

Return on Equity (ROE)	-29.62%
Return on Assets (ROA)	-20.85%
Return on Invested Capital (ROIC)	-21.42%
Return on Capital Employed (ROCE)	-39.53%
Revenue Per Employee	n/a
Profits Per Employee	-$1.20M
Employee Count	74
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +137.08% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+137.08%
50-Day Moving Average	25.28
200-Day Moving Average	19.19
Relative Strength Index (RSI)	94.37
Average Volume (20 Days)	1,755,960

Short Selling Information

The latest short interest is 2.65 million, so 10.31% of the outstanding shares have been sold short.

Short Interest	2.65M
Short Previous Month	2.50M
Short % of Shares Out	10.31%
Short % of Float	20.21%
Short Ratio (days to cover)	14.74

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-102.45M
Pretax Income	-35.69M
Net Income	-88.47M
EBITDA	-102.41M
EBIT	-102.45M
Earnings Per Share (EPS)	-$3.44

Balance Sheet

The company has $239.23 million in cash and $145,000 in debt, giving a net cash position of $239.09 million or $9.28 per share.

Cash & Cash Equivalents	239.23M
Total Debt	145,000
Net Cash	239.09M
Net Cash Per Share	$9.28
Equity (Book Value)	259.19M
Book Value Per Share	10.09
Working Capital	239.01M

Cash Flow

In the last 12 months, operating cash flow was -$86.28 million and capital expenditures -$25,000, giving a free cash flow of -$86.30 million.

Operating Cash Flow	-86.28M
Capital Expenditures	-25,000
Free Cash Flow	-86.30M
FCF Per Share	-$3.35

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Tourmaline Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-53.98%
Shareholder Yield	-53.98%
Earnings Yield	-7.20%
FCF Yield	-7.02%

Analyst Forecast

The average price target for Tourmaline Bio is $47.04, which is -1.38% lower than the current price. The consensus rating is "Hold".

Price Target	$47.04
Price Target Difference	-1.38%
Analyst Consensus	Hold
Analyst Count	12
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	11.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1